The bundle of magnets at the heart of the U.S. Department of Energy's Princeton Plasma Physics Laboratory's (PPPL) National ...

Centromeres, specialized regions located at the center of chromosomes, are critical for ensuring proper cell division. During ...

Italian couple Nicolo and Miriam Vergani have lived in New York’s uptown Harlem neighborhood for more than 20 years. It’s ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer ...

LONDON - AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company, Limited have announced that their drug Enhertu (trastuzumab deruxtecan) has shown a statistically significant improvement in ...

TOKYO & BASKING RIDGE, N.J., May 07, 2025--(BUSINESS WIRE)--Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, ...

Enhertu showed significant improvement in pathologic complete response rates in high-risk HER2-positive early-stage breast cancer compared with standard care. The DESTINY-Breast11 trial indicated ...

And here is the study design. It is a combination of ENHERTU plus pembrolizumab versus ... Transformation of the business structure to one based on new drugs is also progressing steadily.

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

(MENAFN- The Conversation) A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK . This drug is designed to help adults with certain types of ...